Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same author

Detection of hard electrophilic reactive metabolites formed from alicyclic amines using glutathione trapping.

Xenobiotica; the fate of foreign compounds in biological systems·2026
Same author

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends.

Clinical pharmacology and therapeutics·2026
Same author

Strategy for streamlining antibody-drug conjugate pharmacokinetic assays.

Bioanalysis·2026
Same author

Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework.

Clinical pharmacology and therapeutics·2025
Same author

Development of a Robust Platform for Infrared Ion Spectroscopy: A New Addition to the Analytical Toolkit for Enhanced Metabolite Structure Elucidation.

Analytical chemistry·2025

Related Experiment Video

Updated: Jul 8, 2025

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.0K

Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working

Wenkui Li1, Faye Vazvaei-Smith2, Gordon Dear3

  • 1Pharmacokinetic Sciences, Novartis Biomedical Research, East Hanover, New Jersey, USA.

Clinical Pharmacology and Therapeutics
|December 11, 2023
PubMed
Summary

This perspective provides recommendations for fit-for-purpose metabolite bioanalysis during drug development. It outlines strategies for timely identification and characterization of drug metabolites to ensure efficacy and safety.

More Related Videos

An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome
05:35

An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome

Published on: September 20, 2022

3.8K
Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
11:25

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Published on: July 11, 2014

33.7K

Related Experiment Videos

Last Updated: Jul 8, 2025

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.0K
An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome
05:35

An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome

Published on: September 20, 2022

3.8K
Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
11:25

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Published on: July 11, 2014

33.7K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Metabolism and Pharmacokinetics
  • Bioanalytical Chemistry

Background:

  • Metabolites can impact drug efficacy and safety during development.
  • Standard bioanalysis may not fully address metabolite-specific challenges.
  • Timely identification and characterization of metabolites are crucial.

Purpose of the Study:

  • To present recommendations for fit-for-purpose metabolite bioanalysis.
  • To guide the rigor, trigger, and timing of bioanalytical assessments.
  • To support efficient drug development and regulatory submission.

Main Methods:

  • Summarizing considerations for metabolite bioanalysis.
  • Addressing challenges in drug development from preclinical to clinical phases.
  • Defining approaches for metabolite identification and characterization.

Main Results:

  • Provides a framework for metabolite bioanalysis.
  • Ensures timely assessment of efficacy and safety implications.
  • Facilitates efficient drug development pathways.

Conclusions:

  • Fit-for-purpose metabolite bioanalysis is essential for drug development.
  • Recommended approaches enhance metabolite characterization.
  • This strategy supports successful regulatory submissions.